Guardant Health (5GH) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

5GH Analyst Ratings

Strong Buy

20 Buy

0 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Guardant

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

5GH Stock 12 Month Forecast

Average Price Target

€180.84

▲(23.42% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is €180.84 with a high forecast of €200.33 and a low forecast of €160.26. The average price target represents a 23.42% change from the last price of €146.52.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"€52","201":"€201","89.25":"€89.3","126.5":"€126.5","163.75":"€163.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200.32871625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€200.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":180.83994731111113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€180.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":160.262973,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€160.26</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,89.25,126.5,163.75,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,157,160.33297817307692,163.66595634615385,166.99893451923077,170.3319126923077,173.66489086538462,176.99786903846154,180.33084721153847,183.6638253846154,186.99680355769232,190.32978173076924,193.66275990384617,196.9957380769231,{"y":200.32871625,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,157,158.8338421008547,160.6676842017094,162.50152630256412,164.3353684034188,166.1692105042735,168.0030526051282,169.83689470598293,171.67073680683762,173.50457890769232,175.33842100854702,177.17226310940174,179.00610521025644,{"y":180.83994731111113,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,157,157.2509979230769,157.50199584615385,157.75299376923076,158.0039916923077,158.2549896153846,158.50598753846154,158.75698546153845,159.0079833846154,159.2589813076923,159.50997923076923,159.76097715384614,160.01197507692308,{"y":160.262973,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.62,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.68,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.68,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.4,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.84,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.97,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.3,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.88,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.36,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":136.52,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":157,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€200.33

Average Price Target€180.84

Lowest Price Target€160.26

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Max Masucci

Roth MKM

€178.07

Buy

21.53%

Upside

Initiated

10/22/26

Guardant Health initiated with a Buy at Roth CapitalGuardant Health initiated with a Buy at Roth Capital

Kallum Titchmarsh

Morgan Stanley

€178.07

Buy

21.53%

Upside

Reiterated

10/20/26

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Alvotech (NASDAQ: ALVO)

Eve Burstein

Bernstein

€186.97

Buy

27.61%

Upside

Assigned

10/19/26

Bernstein Remains a Buy on Guardant Health (GH)

Casey Woodring

J.P. Morgan

€173.62

Buy

18.49%

Upside

Reiterated

10/14/26

Analysts' Top Healthcare Picks: Agilent (A), Guardant Health (GH)

Lu Li

Bank of America Securities

€173.62→€178.07

Buy

21.53%

Upside

Reiterated

10/09/26

Guardant Health price target raised to $200 from $195 at BofAGuardant Health price target raised to $200 from $195 at BofA

Luke Sergott

Barclays

€178.07→€195.88

Buy

33.69%

Upside

Reiterated

10/07/26

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

Subbu Nambi

Guggenheim

€169.17→€178.07

Buy

21.53%

Upside

Reiterated

10/01/26

Guardant Health price target raised to $200 from $190 at GuggenheimGuardant Health price target raised to $200 from $190 at Guggenheim

Evie Koslosky

Goldman Sachs

€186.97→€200.33

Buy

36.72%

Upside

Reiterated

09/20/26

Guardant Health (GH) Gets a Buy from Goldman Sachs

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

09/15/26

Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)

David Westenberg

Piper Sandler

€171.84

Buy

17.28%

Upside

Reiterated

09/15/26

Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)

Doug Schenkel

UBS

€155.81→€200.33

Buy

36.72%

Upside

Reiterated

09/09/26

Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS

Matt Larew

William Blair

―

Buy

―

Reiterated

09/08/26

Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating

Jamie Clark

Rothschild & Co Redburn

€180.74

Buy

23.36%

Upside

Initiated

09/08/26

Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn

Mark Massaro

BTIG

€173.62

Buy

18.49%

Upside

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)

Bradley Bowers

Mizuho Securities

€178.07

Buy

21.53%

Upside

Reiterated

08/04/26

Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Max Masucci

Roth MKM

€178.07

Buy

21.53%

Upside

Initiated

10/22/26

Guardant Health initiated with a Buy at Roth CapitalGuardant Health initiated with a Buy at Roth Capital

Kallum Titchmarsh

Morgan Stanley

€178.07

Buy

21.53%

Upside

Reiterated

10/20/26

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH) and Alvotech (NASDAQ: ALVO)

Eve Burstein

Bernstein

€186.97

Buy

27.61%

Upside

Assigned

10/19/26

Bernstein Remains a Buy on Guardant Health (GH)

Casey Woodring

J.P. Morgan

€173.62

Buy

18.49%

Upside

Reiterated

10/14/26

Analysts' Top Healthcare Picks: Agilent (A), Guardant Health (GH)

Lu Li

Bank of America Securities

€173.62→€178.07

Buy

21.53%

Upside

Reiterated

10/09/26

Guardant Health price target raised to $200 from $195 at BofAGuardant Health price target raised to $200 from $195 at BofA

Luke Sergott

Barclays

€178.07→€195.88

Buy

33.69%

Upside

Reiterated

10/07/26

Barclays Sticks to Its Buy Rating for Guardant Health (GH)

Subbu Nambi

Guggenheim

€169.17→€178.07

Buy

21.53%

Upside

Reiterated

10/01/26

Guardant Health price target raised to $200 from $190 at GuggenheimGuardant Health price target raised to $200 from $190 at Guggenheim

Evie Koslosky

Goldman Sachs

€186.97→€200.33

Buy

36.72%

Upside

Reiterated

09/20/26

Guardant Health (GH) Gets a Buy from Goldman Sachs

William Bonello

Craig-Hallum

―

Buy

―

Reiterated

09/15/26

Analysts Are Bullish on These Healthcare Stocks: NeurAxis, Inc. (NRXS), Guardant Health (GH)

David Westenberg

Piper Sandler

€171.84

Buy

17.28%

Upside

Reiterated

09/15/26

Piper Sandler Sticks to Their Buy Rating for Guardant Health (GH)

Doug Schenkel

UBS

€155.81→€200.33

Buy

36.72%

Upside

Reiterated

09/09/26

Guardant Health assumed with a Buy at UBSGuardant Health assumed with a Buy at UBS

Matt Larew

William Blair

―

Buy

―

Reiterated

09/08/26

Guardant Health: FDA Companion Dx Approval for Camizestrant Validates Longitudinal Liquid Biopsy and Supports Buy Rating

Jamie Clark

Rothschild & Co Redburn

€180.74

Buy

23.36%

Upside

Initiated

09/08/26

Guardant Health initiated with a Buy at Rothschild & Co RedburnGuardant Health initiated with a Buy at Rothschild & Co Redburn

Mark Massaro

BTIG

€173.62

Buy

18.49%

Upside

Reiterated

09/01/26

Analysts Offer Insights on Healthcare Companies: Guardant Health (NASDAQ: GH), NRX Pharmaceuticals (NASDAQ: NRXP) and Innate Pharma (NASDAQ: IPHA)

Bradley Bowers

Mizuho Securities

€178.07

Buy

21.53%

Upside

Reiterated

08/04/26

Mizuho Securities Reaffirms Their Buy Rating on Guardant Health (GH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

HROWHarrow Health

KURAKura Oncology

DNLIDenali Therapeutics

STOKStoke Therapeutics

CELCCelcuity

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Guardant Health

3 Months

William BonelloCraig-Hallum

Success Rate

10/15 ratings generated profit

Average Return

+37.09%

Copying William Bonello's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +37.09% per trade.

1 Year

Daniel BrennanTD Cowen

Success Rate

17/18 ratings generated profit

Average Return

+108.91%

Copying Daniel Brennan's trades and holding each position for 1 Year would result in 94.44% of your transactions generating a profit, with an average return of +108.91% per trade.

2 Years

Daniel BrennanTD Cowen

Success Rate

18/18 ratings generated profit

Average Return

+242.11%

Copying Daniel Brennan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +242.11% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

5GH Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 5GH has received 31 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 5GH average Analyst price target in the past 3 months is 180.84.

Each month's total comprises the sum of three months' worth of ratings.

5GH Financial Forecast

5GH Earnings Forecast

Next quarter’s earnings estimate for 5GH is -€0.67 with a range of -€0.80 to -€0.57. The previous quarter’s EPS was -€0.80. 5GH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Sales Forecast

Next quarter’s sales forecast for 5GH is €313.08M with a range of €305.65M to €320.47M. The previous quarter’s sales results were €299.03M. 5GH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 5GH has Performed in-line its overall industry.

5GH Stock Forecast FAQ

What is DE:5GH’s average 12-month price target, according to analysts?

Based on analyst ratings, Guardant Health’s 12-month average price target is 180.84.

What is DE:5GH’s upside potential, based on the analysts’ average price target?

Guardant Health has 23.42% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Guardant Health a Buy, Sell or Hold?

Guardant Health has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.

What is Guardant Health’s share price target?

The average share price target for Guardant Health is 180.84. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €200.33 ,and the lowest forecast is €160.26. The average share price target represents 23.42% Increase from the current price of €146.52.

What do analysts say about Guardant Health?

Guardant Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Guardant Health?

To buy shares of DE:5GH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Guardant Health (5GH) Stock Forecast & Price Target

5GH Analyst Ratings

5GH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Guardant Health

5GH Analyst Recommendation Trends

5GH Financial Forecast

5GH Earnings Forecast

5GH Sales Forecast

5GH Stock Forecast FAQ

Detailed List of Analyst Forecasts